Bausch + Lomb

Bausch + Lomb Announces European CE Mark Approval of SeeLyra™ Femtosecond Laser Sep 11 2026 Next-generation platform provides precision and control in laser-assisted preparation for premium cataract, LASIK flap and corneal therapeutic surgeries with live swept source OCT Compact design accommodates today’s space-constrained operating rooms Platform mobility, versatile configurations support efficiency, streamlined workflows VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation...

Bausch + Lomb Announces New Scientific Data, Educational Events at the European Society of Cataract and Refractive Surgery Annual Congress Sep 03 2026 30 data presentations and posters include studies evaluating enVista Aspire™, Artelac®* Complete, LuxLife™, enVista Envy™ and ELIOS™ System Multiple events and demonstrations will enable surgeons to hear from top ophthalmologists and engage with the latest Bausch + Lomb technology VAUGHAN, Ontario, Sept.

Bausch + Lomb Announces New Published Research on enVista Aspire™ Real World Experience Sep 02 2026 Multicenter retrospective case series published in Ophthalmology and Therapy Results demonstrate enVista Aspire and enVista Aspire toric deliver good distance and functional intermediate vision in a majority of patients Study shows these enhanced monofocal lenses can meet digital demands modern cataract patients face This paper and other data on enVista Aspire can be found on Bausch + Lomb’s...

Most Women Don't Recognize Dry Eye as a Symptom of Perimenopause and Menopause, New Bausch + Lomb Survey Finds Sep 01 2026 Only 14% of peri-, menopausal and post-menopausal women recognize dry eye as a menopause-related symptom. 78% of women were surprised to learn that dry eye is a symptom of perimenopause or menopause. Women experiencing dry eye reported impacts on everyday activities including reading, screen use, driving and productivity.

Bausch + Lomb Advancing Two First-in-Class Eye Health Therapies Based on Trial Results Aug 24 2026 Dual-action eye drop targeting both evaporative and inflammatory dry eye disease moving to Phase 3 Positive Phase 1b results for ocular surface pain candidate validate TRPV1 antagonist approach and strengthen confidence in ongoing Phase 2 study Combined potential peak sales exceeding $2 billion assuming successful development and commercialization1 VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch +...

Bausch + Lomb Announces Board of Directors Update, Reaffirms Guidance Aug 06 2026 VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced changes to its Board of Directors. At the request of Bausch Health Companies Inc.

Bausch + Lomb Delivers Broad-Based Second-Quarter Growth, Raises Full-Year 2026 Guidance Jul 29 2026 Revenue of $1.394 Billion Revenue Grew 9% as Reported and 8% on a Constant Currency1 Basis Compared to the Second Quarter of 2025 GAAP Net Loss Attributable to Bausch + Lomb Corporation of $14 Million Adjusted EBITDA (non-GAAP)1 of $241 Million; Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1 of $246 Million Raising Full-Year 2026 Revenue and Adjusted EBITDA Excluding Acquired IPR&D...

Bausch + Lomb Launches EyeGility™ Inserter Preloaded IOL Delivery System in the United States Jul 16 2026 EyeGility is designed for the enVista® family of IOLs Offers balanced push force for smooth delivery, convenient one-handed operation Available now for enVista Aspire™; will be available for enVista Envy™ in the coming months VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live...

Bausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective Candidate Jul 09 2026 Phase 2 study did not meet its primary endpoint. Company will discontinue development of eye drops for glaucoma-related vision improvement but continue pursuing a sustained-release implant for the treatment of vision-threatening disease with a primary focus on geographic atrophy.

Bausch + Lomb Introduces Orphia™, an AI-Powered Digital Health Platform Built to Return Physicians to Patient Care Jul 09 2026 Designed to reduce the operational burden that stands between physicians and their patients. Initial offering focuses on pre-surgery cataract education, with additional AI capabilities for ophthalmology planned over time. Brand agnostic and built to serve all eye care providers.